Mabqi

Mabqi, founded in 2017 and headquartered in France, is emerging as a pivotal player in the Biotechnology industry with its cutting-edge approaches to antibody discovery. Under its slogan, "Your key partner for breakthrough antibody discovery," the company leverages proprietary technology, employing synthetic fully human libraries and pH-sensitive variants designed primarily for oncology applications.

Mabqi's comprehensive service portfolio offers end-to-end solutions that encompass everything from initial antibody discovery to affinity maturation, optimization, and full characterization. This ensures the delivery of high-quality, developable antibodies tailored to specific needs. With a commitment to innovation in therapeutic antibodies, Mabqi presents off-the-shelf antibody assets ready for partnered development and licensing opportunities.

Despite its promising capabilities and opportunities in the biotech space, as of now, Mabqi has not disclosed any recent investments or investor partnerships. This presents a potentially strategic entry point for investors seeking involvement in transformative biotech advancements.